Agenus Inc. (AGEN)
AGEN moved a median of -0.28% 30 minutes after news, and -0.64% by the close. How AGEN actually reacts to news — the realized, point-in-time move the market made, measured across 878 labeled events over the last three years with zero look-ahead.
AGEN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 872 |
| 30-min | -0.28% | 41% | 878 |
| 60-min | -0.35% | 42% | 878 |
| to close | -0.64% | 41% | 867 |
| Middle 50% of AGEN reactions | -1.73% to +1.14% |
|---|---|
| Median reaction (30-min) | -0.28% |
| Measured reactions | 878 |
Half of all Agenus Inc. news events land between -1.73% and +1.14% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How AGEN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 12 | +0.42% | 58% | +3.75% |
| Analyst downgrades | 15 | -4.29% | 13% | -4.96% |
| Rating reiterations | 45 | -1.18% | 33% | -1.92% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how AGEN ranks against every other measured name →
That’s how AGEN usually reacts — get an email when it moves on news →Email me when AGEN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AGEN's baseline. Nothing else.
Recent AGEN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference | Press release | Business Wire | -0.26% | -0.52% | |
| Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer | Press release | Business Wire | -1.32% | -0.27% | |
| Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 | Press release | Business Wire | +0.24% | +4.80% | |
| Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026 | Press release | Business Wire | +2.27% | +0.00% | |
| Form S-3 AGENUS INC | SEC filing · Form S-3 | SEC EDGAR | +0.43% | +2.59% | |
| Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 | Press release | Business Wire | +1.11% | +1.92% | |
| Form S-8 AGENUS INC | SEC filing · Form S-8 | SEC EDGAR | +1.48% | +1.48% | |
| Agenus to Participate in Upcoming September Investor Conferences | Press release | Business Wire | -0.26% | -0.91% | |
| Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism | Press release | Business Wire | -0.13% | -3.16% | |
| Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer | Press release | Business Wire | -0.73% | +0.98% | |
| Form 8-K AGENUS INC For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +0.65% | +7.83% | |
| Form EFFECT AGENUS INC | SEC filing · Form EFFECT | SEC EDGAR | -0.41% | -2.06% | |
| Form 8-K AGENUS INC For: Aug 10 | SEC filing · Form 8-K | SEC EDGAR | +0.30% | +2.19% | |
| Form 8-K AGENUS INC For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +1.01% | -0.14% | |
| Form 10-Q AGENUS INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.66% | — | |
| Form S-3 AGENUS INC | SEC filing · Form S-3 | SEC EDGAR | -3.66% | — | |
| Form S-8 AGENUS INC | SEC filing · Form S-8 | SEC EDGAR | -3.66% | — | |
| Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer | Press release | Business Wire | +4.49% | -2.35% | |
| Form 8-K AGENUS INC For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +4.49% | -2.35% | |
| Agenus to Provide Second Quarter 2026 Financial Report and Development Update | Press release | Business Wire | +3.33% | +0.46% | |
| Form EFFECT AGENUS INC | SEC filing · Form EFFECT | SEC EDGAR | -2.06% | +8.91% | |
| Form S-3 AGENUS INC | SEC filing · Form S-3 | SEC EDGAR | +3.56% | -1.58% | |
| Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026 | Press release | Business Wire | -1.00% | -0.20% | |
| Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer | Press release | Business Wire | +1.20% | +13.33% | |
| Form 8-K AGENUS INC For: Jul 13 | SEC filing · Form 8-K | SEC EDGAR | +1.20% | +13.33% | |
| Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026 | Press release | Business Wire | -0.86% | -2.57% | |
| Form 8-K AGENUS INC For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | -2.75% | +4.17% | |
| Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026 | Press release | Business Wire | +0.67% | -3.03% | |
| Form 8-K AGENUS INC For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | +0.48% | -2.23% | |
| Agenus Announces Virtual 2026 Annual Shareholders Meeting | Press release | Business Wire | +0.30% | -4.17% | |
| Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC | Press release | Business Wire | -1.21% | -5.76% | |
| Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026 | Press release | Business Wire | -1.21% | -5.76% | |
| Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer | Press release | Business Wire | -1.26% | -11.24% | |
| Form 8-K AGENUS INC For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -1.26% | -11.24% | |
| Form DEFA14A AGENUS INC | SEC filing · Form DEFA14A | SEC EDGAR | -0.14% | -0.71% | |
| Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development | Press release | Business Wire | -7.90% | -11.17% | |
| Form 10-Q AGENUS INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.23% | +5.85% | |
| Form 8-K AGENUS INC For: May 11 | SEC filing · Form 8-K | SEC EDGAR | -7.90% | -11.17% | |
| Agenus to Provide First Quarter 2026 Financial Report and Corporate Update | Press release | Business Wire | +1.26% | +2.71% | |
| Form ARS AGENUS INC For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.24% | -0.78% | |
| Form DEF 14A AGENUS INC For: Apr 30 | SEC filing · Form DEF | SEC EDGAR | +0.24% | -0.78% | |
| Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs | Press release | Business Wire | -7.12% | -11.94% | |
| Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026 | Press release | Business Wire | -1.45% | -5.33% | |
| Form PRE 14A AGENUS INC For: Apr 20 | SEC filing · Form PRE | SEC EDGAR | -7.12% | -11.94% | |
| Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer | Press release | Business Wire | +2.86% | -2.86% | |
| Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026 | Press release | Business Wire | +5.19% | +11.87% | |
| Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer | Press release | Business Wire | +0.59% | +0.00% | |
| Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access | Press release | Business Wire | -1.02% | -1.45% | |
| Form 8-K AGENUS INC For: Mar 24 | SEC filing · Form 8-K | SEC EDGAR | -0.29% | -1.71% | |
| Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer | Press release | Business Wire | +1.26% | -5.53% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AGEN section they belong to.
Where else AGEN is measured.
AGEN earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Paratek Pharmaceuticals, Inc. (PRTK) | 891 | -0.18% | 44% |
| TRANSENTERIX (TRXC) | 884 | -0.71% | 39% |
| OncoSec Medical Incorporated (ONCS) | 878 | -0.49% | 39% |
| Genocea Biosciences, Inc. (GNCA) | 873 | -0.47% | 40% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Agenus Inc.'s median reaction calculated?
Every labeled AGEN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 878 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of AGEN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AGEN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.